Figure 2

Neutralization of VOCs and VUM by day-60 sera from high and moderate responders. The activity of vaccinees’ sera to block the infectivity and replication of 9 SARS-CoV-2 variants (Alpha variants: SARS-CoV-2^QHN001, SARS-CoV-2^QK002, and SARS-CoV-2^QHN002; a Beta variant: SARS-CoV-2^TY8-612; a Gamma variant: SARS-CoV-2^TY7-501; a Delta variant: SARS-CoV-2^K1734; a Kappa variant: SARS-CoV-2^K5356; and E484K variants: SARS-CoV-2⁷⁶¹⁰⁷ and SARS-CoV-2⁷⁶¹³⁷) were evaluated. A Wuhan strain SARS-CoV-2^05-2N was employed as a reference SARS-CoV-2. Left panel shows results of high responders (n = 15), whereas right panel shows the results of moderate responders (n = 30). The NT₅₀ titers of each serum against SARS-CoV-2 variant are shown in red (high responders) or blue (moderate responders) circles, and bar represent average NT₅₀ titer of each group. P values for the difference between SARS-CoV-2^05-2N and each variant of high responders or moderate responders: < 0.001 (QHN001), < 0.001 (QK002), < 0.001 (QHN002), < 0.001 (TY8-612), < 0.001 (TY7-501), < 0.001 (K1734), < 0.001 (K5356), < 0.001 (76107), and < 0.001 (76137).